Skip to content

Entities Organizations Interius BioTherapeutics

Organization · Biotech

Last updated 2026-04-10

Confirmed

Interius BioTherapeutics

Interius BioTherapeutics is a clinical-stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity, and beyond. The company's proprietary LENTIVECTOR platform enables in vivo generation of CAR T and CAR NK cells through a single intravenous infusion, offering a potential off-the-shelf, scalable alternative to traditional ex vivo cell therapies.

Not to be confused with similarly named companies; this entity is a biotechnology firm focused on in vivo cell and gene therapy. Acquired by Kite, a Gilead Company.

Extended Facts

Legal name Interius BioTherapeutics, Inc.
Founded 2019
General info@interiusbio.com
Team size ~11-50 (2025)
Address 3401 Grays Ferry Ave, Building 200, Suite 300, Philadelphia, PA, 19146, US

Relationships

People

Phil Johnson President and CEO

Products

Verified Profiles

Cross-platform entity consensus: 2 independent sources

SameAs links connect this entity to its canonical presence across authoritative platforms.